Zynext Ventures USA, the Venture Capital (VC) arm of Zydus Lifesciences (Zydus), committed to advancing disruptive breakthroughs in healthcare, announced its investment in neuro42, a US-based developer of cutting-edge portable MRI systems for neuroimaging and interventions.
neuro42 is transforming neuroimaging and interventions with their portable MRI and robotic intervention technology, bringing advanced imaging and treatment to the patient’s bedside. Their compact, user-friendly MRI scanner enables rapid diagnosis, while the robotic module promises to revolutionize procedures like brain biopsies and ablations. neuro42’s Diagnostic MRI platform is FDA 510(K) cleared for neuroimaging, and the company is currently seeking regulatory clearance for its interventional module.
Jay Kothari, Director of Zynext Ventures, highlighted the investment’s strategic importance, saying, “neuro42’s disruptive technology has the potential to reshape neuroimaging and interventions, enabling precise planning and execution of surgical procedures like shunts, biopsies, and laser therapy. Our investment will propel their progress and bring groundbreaking solutions to patients.”
“We are delighted to have Zynext as our strategic investor,” said Dr. Amit Vohra, Founder and CEO of neuro42. “The partnership will accelerate our mission in bringing our innovational neuroimaging and interventional products to global masses.”
The US MRI imaging market was valued at ~$1.8bn in 2024, with neurology accounting for 23% of this market. As per Center for Disease Control (CDC), there are 2.8 million cases of traumatic brain injury (TBI), 795,000 strokes, and 14,000 brain biopsies each year in the US alone. neuro42 is well-positioned to address this demand and revolutionize the space.
